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We identified 39 sIOp-UKCCsG pNeT3 survivors for whom clinical, HrQoL, and molecular subgroup data had been assessed (supplementary Table 1 ). Tumours were categorised into the sHH, WNT and non-sHH/non-WNT subgroups (comprising Group 3 and Group 4 tumours) as previously described [3, 4, 8] . We combined Groups 3 and 4 together as only a subset of those classified as nonsHH/WNT [3] were sub-classified as Group 3 or 4 [8] leaving small numbers with similar HrQoL scores in the two Groups. Age at diagnosis, age at HrQoL [2] assessment, time from diagnosis to HrQoL [2] assessment, gender, pre-operative neurology, post-operative complications, extent of resection, pathological subtype, tumour metastatic stage, MYC and MYCN amplification status, and treatment received were documented and assessed within each molecular subgroup (supplementary Table 1 ).
The distribution of scores for quality of survival (at a mean interval of 7 years from diagnosis) using the health utilities index total utility score (HUI3, a measure of health status), the strengths and difficulties questionnaire total difficulties score (sDQ, a measure of emotional and behavioural difficulties), and the pediatric quality of life inventory total score (pedsQL, a measure of HrQoL) [2] , showed differences in patterns between tumour molecular subgroups. The sHH subgroup showed a trend to better functioning across all indices tested ( Fig. 1a; supplementary Table 2 ), and univariate analyses (Kruskal-Wallis reduced health-related quality of life (HrQoL), including impaired cognitive, social, physical, behavioural and emotional functioning, is common in children treated for medulloblastoma [1, 2, 7] and has been associated with clinical factors such as surgical resection and treatment modality [2, 5, 6] . recent biological advances have allowed the distinction of medulloblastomas into four consensus molecular subgroups-WNT, sHH, Group 3 and Group 4-which display distinct molecular, clinical, and pathological disease characteristics [3, 4, 8, 9] . Together, these observations raise the hypothesis that HrQoL in medulloblastoma survivors may be related to their underlying tumour biology.
We have previously reported the extensive characterisation of clinical outcomes [10] , HrQoL [2] , and biomarkerdriven prognostication schemes [4] for children with tests) revealed the overall inter-group difference for the parent-reported pedsQL total score for HrQoL was statistically significant (supplementary Table 2 ). subsequent comparisons of these HrQoL scores between each of three molecular subgroups (Mann-Whitney U tests) showed significant differences between sHH and WNT, and between sHH and non-sHH/non-WNT (supplementary Table 2 ).
We next examined this inter-group difference in parentreported HrQoL using multivariate analyses, that included factors previously associated with worse HrQoL outcomes in childhood brain tumours [1] , to determine whether the impact of the sHH subgroup remained. predictors were placed in the model in a hierarchical forward step-wise fashion and were retained if p < 0.1, beginning with sHH vs. all others at step one, followed by gender, age at diagnosis, and interval from diagnosis at step two and, lastly at step 3, by treatment given (either craniospinal irradiation alone or craniospinal irradiation plus chemotherapy) and the presence (or not) of cerebellar mutism (Fig. 1b) . At each step, sHH remained the only significant predictor of parent-report HrQoL.
In spite of WNT patients displaying a better prognosis [4, 8] , our analysis indicates patients with sHH subgroup tumours are associated with better parent-report HrQoL, even after taking into consideration other possible HrQoL predictors. The larger effect on parent-than self-report of HrQoL is consistent with the larger effects reported by parents in all 108 patients that participated in the pNeT3 Qos study [2] . Further studies to expand and validate these observations, and to determine any clinico-biological correlates and mechanisms, are now paramount. such studies should also determine whether tumour location in the cerebellum, not available to us for the sample described here, and recently reported to vary with tumour subtype [11] , may be on the pathway from biological tumour subtype to HrQoL. Although the modest cohort size precluded more detailed analysis, our initial investigations suggest that combined biological and quality of survival investigations have the potential to inform our understanding of HrQoL outcomes, and could impact subgroup-directed disease management strategies in the future.
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